Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1647158 | 0.86 | HPGDS (0.43) | — | |
| SCHEMBL1646361 | 0.82 | SCN9A (0.46) | SCN9A | |
| SCHEMBL31464234 | 0.82 | SCN9A (0.46) | SCN9A | |
| SCHEMBL31364306 | 0.80 | MAPT (0.48) | MAPTNPC1RAB9AALDH1A1PKM | |
| SCHEMBL1647788 | 0.79 | ALDH1A1 (0.41) | MAPTNPC1RAB9AALDH1A1PKM | |
| SCHEMBL31364291 | 0.78 | ALDH1A1 (0.49) | MAPTRAB9AALDH1A1LMNAKMT2A | |
| SCHEMBL1647065 | 0.77 | — | — | |
| SCHEMBL6157002 | 0.76 | MAPT (0.62) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL3708038 | 0.76 | CDC7 (0.48) | MAPTNPC1RAB9AALDH1A1PKM | |
| SCHEMBL31464228 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| EP-2467378-B1 | COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD (KR) | 2016-07-27 | — | — | EP | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8729273-B2 | Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | LG LIFE SCIENCES LTD. (KR) | 2014-05-20 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG CHEM, LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| EP-2467378-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG Life Sciences Ltd (KR) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043568-A2 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES LTD. (KR) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184582-A1 | NOVEL COMPOUNDS EFFECTIVE AS XANTHINE OXIDASE INHIBITORS, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | XDH, PNPO, AOX1 | MAPT 3082/4885NPC1 1843/4885RAB9A 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.